首页
订购/客服:400-666-5481

GSK1904529A,IGF-1R / IR酪氨酸激酶抑制剂

    
≥98%

GSK1904529A

源叶(MedMol)
S80082 一键复制产品信息
1089283-49-7
C44H47F2N9O5S
851.96
N-(2,6-difluorophenyl)-5-(3-(2-(5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)H-imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide;GSK1904529A
货号 规格 价格 上海 北京 珠海 重庆 武汉 购买数量
S80082-5mg促销
≥98%

¥300.00 ¥270.00

2 - - - -
S80082-10mg促销
≥98%

¥596.00 ¥536.00

2 - - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品
产品描述: GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity
靶点: IC50: 27 nM (IGF-1R), 25 nM (IR);Apoptosis;Raf;VEGFR;IGF-1R;Syk
体内研究: GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has antitumor activity in mice. GSK1904529A (1-30 mg/kg; a single p.o.) decreases IGF-I-induced IGF-IR phosphorylation in a dose-dependent manner in mice. GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has no significant alterations in the blood glucose levels in mice
参考文献: 1. Sabbatini P, et al. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res, 2009, 15(9), 3058-3067. 2. Zhou Q, et, al. GSK1904529A, an insulin-like growth factor-1 receptor inhibitor, inhibits glioma tumor growth, induces apoptosis and inhibits migration. Mol Med Rep. 2015 Sep;12(3):3381-3385.
溶解性: Soluble  in  DMSO
保存条件: -20℃
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 1.174 ml 5.869 ml 11.738 ml
5 mM 0.235 ml 1.174 ml 2.348 ml
10 mM 0.117 ml 0.587 ml 1.174 ml
50 mM 0.023 ml 0.117 ml 0.235 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×